Zogenix to have Significant Presence at 12th European

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zogenix to have Significant Presence at 12th European Congress on Epileptology

EMERYVILLE, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the Company is sponsoring four poster presentations at the 12 th European Congress on Epileptology (ECE), taking place this week in Prague, Czech Republic.  One poster will feature an update on the efficacy and safety data on ZX008 (low-dose fenfluramine) as an adjunctive therapy for seizures associated with Dravet syndrome from the new patient cohort included in the ongoing Belgian open-label study.  This poster will primarily be an encore of the data that were presented in a podium presentation at the 14 th International Child Neurology Congress in May 2016.

The three burden of illness-related poster presentations will focus on better understanding the burden Dravet syndrome causes for the patient and their family, and also on identifying clinically relevant outcome measures to assess the impact on the lives of Dravet syndrome patients and their caregivers. 

Once the last poster is presented, all four posters will be available here: http://www.zogenix.com/c/newsroom/publication...ations.php .                                                                                                                   “Our presence at ECE, and our collaborative research into the disease burden of Dravet syndrome, is indicative of Zogenix’s commitment to patients and their families affected by epilepsy,” said Stephen J. Farr, Ph.D., President and CEO.  “Importantly, we remain encouraged by the continued meaningful reduction in seizure frequency and sustained cardiovascular safety being demonstrated in the ongoing Belgian open-label study.  We are also dedicated to identifying the core clinically relevant quality of life-related outcome measures associated with this devastating condition to better reflect the impact treatments may have.  In addition, our ZX008 Phase 3 program for Dravet syndrome continues to enroll patients in the U.S. and internationally, and Zogenix expects that the U.S. and European submissions for market authorization for ZX008 in Dravet syndrome will occur in 2017.”

ZX008 is designated as an orphan drug in both the U.S. and Europe, and also received Fast Track designation in the U.S., for the treatment of Dravet syndrome.

Zogenix at the 12 th European Congress on Epileptology

Title: Fenfluramine Significantly Reduces Seizure Frequency in Dravet Syndrome:  A Prospective Study of a New Cohort of Patients Date: Tuesday 13th September 1:00-2:30 pm Poster Session #: P593

Title: Describing the Humanistic Burden of Illness in Dravet Syndrome – Important Questions Remain Date: Wednesday 14th September 1:00-2:30 pm Poster Session #: P283

Title: What areas of lives of caregivers of children with severe, refractory epilepsy are affected by caregiving?  An expert panel report Date: Wednesday 14th September 1:00-2:30 pm Poster Session #: P214

Title: Towards a Composite Clinical Endpoint: Identifying a Core Set of Patient and Caregiver Relevant Outcome Measures Through Qualitative Research on the Global Impact of Dravet Syndrome Date: Wednesday 14th September 1:00-2:30 pm Poster Session #: P293

About the ZX008 Phase 3 Program The Zogenix study entitled, "A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome," is being conducted for patients with Dravet syndrome whose seizures are not adequately controlled on their current seizure medication. For more information, please visit www.clinicaltrials.gov listing (NCT02682927).

About Zogenix Zogenix, Inc. (Nasdaq: ZGNX ) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit  www.zogenix.com .

Forward Looking Statements Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the timing of the commencement of the second Phase 3 clinical study for ZX008 and ZX008’s potential as a treatment for seizures associated with Dravet syndrome. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix's business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product candidates such as ZX008, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier clinical trials and studies may not be predictive of future results; Zogenix's reliance on third parties to conduct its clinical trials, enroll patients, manufacture its preclinical and clinical drug supplies and manufacture commercial supplies of its drug products, if approved; unexpected adverse side effects or inadequate therapeutic efficacy of ZX008 that could limit approval and/or commercialization, or that could result in recalls or product liability claims; Zogenix's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its product development activities; Fast Track designation may not result in an expedited regulatory review process; and other risks described in Zogenix's prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | Andrew@lifesciadvisors.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 306

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 0

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 635

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Cordance Medical Secures $8M Seed Funding for Brain Solutions

Updated Category News Views 235

Groundbreaking Seed Financing for Cordance Medical Cordance Medical, a leader in noninvasive focused ultrasound technology for treating brain diseases, has successfully completed an oversubscribed seed financing round. This milestone was highlighted by exceeding the initial $8 million target, with participation from both new and existing investors such as Shanda Grab...

Continue Reading
Man Group PLC Discloses Open Positions for Aviva PLC

Updated Category News Views 179

Man Group PLC Reports on Relevant Securities In a significant disclosure, Man Group PLC has announced its public opening position in relation to Aviva PLC, emphasizing transparency in its dealings concerning relevant securities. The regulations governing such disclosures necessitate comprehensive reporting, particularly when interests exceed 1% of the relevant securities....

Continue Reading
Baird Raises Griffon Corp Price Target to $92, Outperform Rating

Updated Category News Views 63

Baird Updates Griffon Corp's Stock Projection Baird has elevated its price target on shares of Griffon Corp (NYSE: GFF) from $84.00 to $92.00. This revision to the target price comes with a maintained Outperform rating, signaling strong confidence in the company's outlook. The analyst from Baird forecasts a gradual increase in Griffon's fiscal fourth-quarter financial...

Continue Reading
Experience SoCal Car Culture at SPARQ's LA Auto Show Exhibit

Updated Category News Views 316

SPARQ Returns to LA Auto Show with Exciting Exhibit California's automotive AI startup SPARQ is making waves by returning to the highly anticipated Los Angeles Auto Show this November. This year, visitors can expect an immersive experience inside the Concourse Hall, showcasing an impressive lineup of hypercars, Formula 1 vehicles, and famous cars from iconic films such as...

Continue Reading
Sagent Behavioral Health: A New Era for Mental Wellness Providers

Updated Category News Views 616

Sagent Behavioral Health: Transforming Behavioral Healthcare Sagent Behavioral Health marks a significant advancement in the provision of mental health services in the Midwest. With the consolidation of Nystrom & Associates and its affiliated brands, including Ellie Mental Health, LifeWorks, and several others, this new entity aims to create a unified and robust network...

Continue Reading